Literature DB >> 20581723

Effects of soy isoflavones and genistein on glucose metabolism in perimenopausal and postmenopausal non-Asian women: a meta-analysis of randomized controlled trials.

Elena Ricci1, Sonia Cipriani, Francesca Chiaffarino, Matteo Malvezzi, Fabio Parazzini.   

Abstract

OBJECTIVE: Several randomized controlled trials (RCTs) have examined the role of soy isoflavones on cardiovascular risk factors in perimenopausal and postmenopausal women and have yielded inconsistent results. This meta-analysis aimed to assess the overall effect of soy isoflavones on glucose metabolism: fasting blood glucose, insulin, and insulin resistance.
METHODS: We searched for all articles published in English and indexed in Medline from January 1990 to December 2009. We included RCTs for soy isoflavone supplementation in perimenopausal and postmenopausal women not taking hormone therapy, selecting non-Asian women only. The main outcomes were fasting blood glucose changes from baseline.
RESULTS: We identified 10 eligible RCTs containing blood glucose data of 794 women. The main result was that soy isoflavones did not affect fasting blood glucose significantly. Under a random-effects model, the average difference in fasting blood glucose values between women assigned to isoflavones and women assigned to placebo was -2.16 mg/dL (95% CI, -5.21 to 0.89 mg/dL; P = 0.17). In genistein studies, the mean difference was -7.15 mg/dL (95% CI, -11.47 to -2.82). However, the effects on insulin and homeostasis model assessment insulin resistance were significant: -1.37 microIU/mL (95% CI, -1.92 to -0.81 microIU/mL) and -0.39 (95% CI, -0.65 to -0.14), respectively. Subgroup analyses did not show a significant effect of isoflavone dose, whereas isoflavone mixtures and genistein had a different effect on fasting blood glucose.
CONCLUSIONS: This meta-analysis of RCTs showed that isoflavone use was not associated with a significant glycemia reduction in perimenopausal and postmenopausal non-Asian women. However, the few studies that reported insulin and homeostasis model assessment insulin resistance changes suggested that soy isoflavones and genistein alone had a beneficial effect on glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20581723     DOI: 10.1097/gme.0b013e3181dd05a9

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  15 in total

1.  Urinary isoflavone concentrations are inversely associated with cardiometabolic risk markers in pregnant U.S. women.

Authors:  Ling Shi; Heather Harker Ryan; Emily Jones; Tiffany A Moore Simas; Alice H Lichtenstein; Qi Sun; Laura L Hayman
Journal:  J Nutr       Date:  2013-12-31       Impact factor: 4.798

2.  Urinary isoflavonoids and risk of type 2 diabetes: a prospective investigation in US women.

Authors:  Ming Ding; Adrian A Franke; Bernard A Rosner; Edward Giovannucci; Rob M van Dam; Shelley S Tworoger; Frank B Hu; Qi Sun
Journal:  Br J Nutr       Date:  2015-09-15       Impact factor: 3.718

3.  Soy provides modest benefits on endothelial function without affecting inflammatory biomarkers in adults at cardiometabolic risk.

Authors:  Elizabeth J Reverri; Colette D LaSalle; Adrian A Franke; Francene M Steinberg
Journal:  Mol Nutr Food Res       Date:  2014-12-05       Impact factor: 5.914

4.  Evaluation of Hypoglycemic and Antioxidant Activities of Soybean Meal Products Fermented by Lactobacillus plantarum FPS 2520 and Bacillus subtilis N1 in Rats Fed with High-Fat Diet.

Authors:  Chung-Hsiung Huang; Chun-Lung Chen; Chen-Che Shieh; Shun-Hsien Chang; Guo-Jane Tsai
Journal:  Metabolites       Date:  2022-05-14

5.  Genistein exposure during the early postnatal period favors the development of obesity in female, but not male rats.

Authors:  Rita S Strakovsky; Stéphane Lezmi; Jodi A Flaws; Susan L Schantz; Yuan-Xiang Pan; William G Helferich
Journal:  Toxicol Sci       Date:  2013-12-21       Impact factor: 4.849

6.  Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2 diabetes: a 1-year, double-blind, randomized, controlled trial.

Authors:  Peter J Curtis; Mike Sampson; John Potter; Ketan Dhatariya; Paul A Kroon; Aedín Cassidy
Journal:  Diabetes Care       Date:  2012-01-16       Impact factor: 19.112

7.  Dietary isoflavone intake, urinary isoflavone level, and their relationship with metabolic syndrome diagnostic components in korean postmenopausal women.

Authors:  Mi Hyun Kim; Yun Jung Bae
Journal:  Clin Nutr Res       Date:  2013-01-29

Review 8.  Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective.

Authors:  Elisabetta Poluzzi; Carlo Piccinni; Emanuel Raschi; Angela Rampa; Maurizio Recanatini; Fabrizio De Ponti
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Consumption of soy foods and isoflavones and risk of type 2 diabetes: a pooled analysis of three US cohorts.

Authors:  M Ding; A Pan; J E Manson; W C Willett; V Malik; B Rosner; E Giovannucci; F B Hu; Q Sun
Journal:  Eur J Clin Nutr       Date:  2016-07-06       Impact factor: 4.016

Review 10.  Dietary Polyphenols, Mediterranean Diet, Prediabetes, and Type 2 Diabetes: A Narrative Review of the Evidence.

Authors:  Marta Guasch-Ferré; Jordi Merino; Qi Sun; Montse Fitó; Jordi Salas-Salvadó
Journal:  Oxid Med Cell Longev       Date:  2017-08-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.